- Conditions
- Anemia, Sickle Cell
- Interventions
- Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 1,323
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
- Interventions
- MEK162
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Triple Negative Breast Cancer, Residual Disease
- Interventions
- Tetrathiomolybdate, Capecitabine, Pembrolizumab
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Lebanon, New Hampshire • New York, New York
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Epoetin alfa or Epoetin beta
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 823 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Vadadustat, Erythropoiesis Stimulating Agent
- Drug
- Lead sponsor
- USRC Kidney Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more
- Conditions
- Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
- Interventions
- Low intensity anticoagulation, Moderate Intensity Anticoagulation
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
- Interventions
- Screening, Brief Intervention, Referral to Treatment (SBIRT)
- Behavioral
- Lead sponsor
- Shirish S Barve
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Covid19
- Interventions
- C144-LS and C-135-LS
- Biological
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Peripheral Arterial Disease
- Interventions
- Shockwave Lithoplasty® Peripheral Lithoplasty System, Medtronic IN.PACT (DCB)
- Device · Drug
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 33 more
- Conditions
- Coronary Artery Disease
- Interventions
- Hybrid Coronary Revascularization (isolated LIMA-LAD), Hybrid Coronary Revascularization (PCI), Percutaneous Coronary Intervention
- Procedure · Device
- Lead sponsor
- Emilia Bagiella
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 39
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 31 more
- Conditions
- Infection
- Interventions
- Targeted Infection Control
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Nicotine Dependence
- Interventions
- Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Dental Caries
- Interventions
- Nano Silver Fluoride / NSF
- Device
- Lead sponsor
- A.T. Still University of Health Sciences
- Other
- Eligibility
- 6 Years to 10 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- HER2-positive Breast Cancer
- Interventions
- RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy
- Other · Drug
- Lead sponsor
- OmicsWay Corp.
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 40 participants
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Walnut, California
- Conditions
- Infants in Neonatal Intensive Care Units
- Interventions
- Education Plus (E+), Clinical Decision Support, Prescriber Audit and Feedback
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Not listed
- Enrollment
- 6,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Wilmington, Delaware • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Cancer, Cancer, Lung
- Interventions
- CPO301
- Drug
- Lead sponsor
- Conjupro Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
- Drug · Radiation
- Lead sponsor
- Julie E. Bauman, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)
- Interventions
- CC-97540
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Breast Cancer Triple Negative
- Interventions
- Mirvetuximab Soravtansine (IMGN853)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Action Video Game Treatment
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 12 Years to 22 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Cancer
- Interventions
- AGEN1777, a PD-1 inhibitor
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Pancreas Adenocarcinoma
- Interventions
- CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Intensity-modulated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Advanced Solid Tumors
- Interventions
- Dalutrafusp alfa, mFOLFOX6 Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more